
(hereinafter "TR-700"), i.e., 5R)-3-{3-Fluoro-4-[6-(2-methyl-2H-l,2,3,4-tetrazol-5-yl)-pyridin-3-yl]-phenyl}-5-hydroxymethyl-l,3-oxazolidin-2-one, in an amount less than 1%.


[0012] The crystalline free acid may have one or more of the attributes described herein.

[0013] There is provide a purified crystalline (*R*)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, i.e., the free acid, has a purity of at least about 96% by weight. In some embodiments, the crystalline free acid has a median volume diameter of at least about 1.0μm.

[0013a] In one aspect, there is provided crystalline particles comprising at least 96% of (*R*)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluoro-phenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate; and at least one compound of:




, or



.


[0014] In some embodiments, pharmaceutical composition comprises the free acid or a salt thereof and at least one pharmaceutically acceptable carrier, excipient or diluent.

[0014a] In another aspect, there is provided a pharmaceutical composition comprising a lyophilisate of the reaction mixture as defined herein, the pharmaceutical composition comprising:




wherein R=PO(ONa)2,

and at least one compound of:



or



, and

at least one pharmaceutically acceptable carrier, excipient or diluent.

[0015] In some embodiments, a method of treating a bacterial infection comprises administering an effective amount of the crystalline free acid, or a salt thereof to a subject in need thereof. Methods may also include comprise treating a bacterial infection comprising administering the free acid, pharmaceutical composition thereof or a salt to a subject in need thereof.

[0015a] In another aspect, there is provided a pharmaceutical composition for treating a bacterial infection comprising the particles as defined herein and at least one pharmaceutically acceptable carrier, excipient or diluent.

[0015b] In another aspect, there is provided use of the crystalline particles as defined herein or the composition as defined herein in the manufacture of a medicament for treating a bacterial infection.

[0015c] In another aspect, there is provided use of the pharmaceutical composition as defined herein in the manufacture of a medicament for treating a bacterial infection in a subject in need thereof.

[0016] There are also provided processes for making the free acid comprise drying crystallized (*R*)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxy-methyl oxazolidin-2-one dihydrogen phosphate, or a pharmaceutical composition comprising the salt thereof.

[0016a] In another aspect, there is provided a process for making the crystalline particles as defined herein, comprising

adding a reaction mixture comprising a salt of crystalline (*R*)-3-(4-(2-(2-methyl-tetrazol-5-yl)pyridin-5-yl)-3-fluoro-phenyl)-5-hydroxy-methyl oxazolidin-2-one dihydrogen phosphate to an acid solution to thereby form crystallized (*R*)-3-(4-(2-(2-methyl-tetrazol-5-yl)pyridin-5-yl)-3-fluoro-phenyl)-5-hydroxy-methyl oxazolidin-2-one dihydrogen phosphate;

filtering the crystallized (*R*)-3-(4-(2-(2-methyl-tetrazol-5-yl)pyridin-5-yl)-3- fluoro-phenyl)-5-hydroxy-methyl oxazolidin-2-one dihydrogen phosphate from a supernatant; and

drying the resulting crystallized (*R*)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate.

[0016b] In another aspect, there is provided a reaction mixture comprising the crystalline particles as defined herein and a base.

[0017] These and other embodiments are described in greater detail below.

BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 the FT-Raman spectrum of crystalline **1** (R = $PO(OH)_2$).

[0019] Figure 2 shows the X-ray powder pattern of crystalline **1** (R = $PO(OH)_2$).

[0020] Figure 3 shows the differential scanning calorimetry (DSC) thermogram of crystalline **1** (R = $PO(OH)_2$).


[0021] Figure 4 shows the ^1H NMR spectrum of **1** (R = $PO(OH)_2$).

[0022] Figure 5 depicts the TG-FTIR diagram of crystalline **1** (R = $PO(OH)_2$).


[0023] Figure 6 is a diagram showing the dynamic vapor sorption (DVS) behavior of crystalline **1** (R = $PO(OH)_2$).

WHAT IS CLAIMED IS:

1. Crystalline particles comprising at least 96% of (*R*)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluoro-phenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate; and at least one compound of:




, or




.

2. The crystalline particles according to claim 1, wherein said particles furhter comprise at least one compound of:




. or




.


3. The crystalline particles according to claim 2, wherein said particles further comprise the following compound:




4. The crystalline particles of claim 3, wherein said particles further comprise at least one compound of:



, or



5. The crystalline particles according to claim 4, wherein said particles further comprise the compound:



6. The crystalline particles of any one of claims 1-5 having an X-ray diffraction pattern comprising the following peaks: 14.7°, 15.2°, 16.6°, 20.3°, 26.8°, and 28.2°.

7. The crystalline particles of any one of claims 1-6 wherein a median volume diameter is of at least about 1.0μm.

8. A pharmaceutical composition for treating a bacterial infection comprising the particles of any of claims 1-7 and at least one pharmaceutically acceptable carrier, excipient or diluent.

9. The pharmaceutical composition of claim 8 wherein the pharmaceutically acceptable carrier, excipient or diluent is at least one of mannitol, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, or magnesium stearate.

10. Use of the crystalline particles of any one of claims 1-7 or the composition of claims 8-9 in the manufacture of a medicament for treating a bacterial infection.

11. A process for making the crystalline particles of claims 1-7, comprising

adding a reaction mixture comprising a salt of crystalline (*R*)-3-(4-(2-(2-methyl-tetrazol-5-yl)pyridin-5-yl)-3-fluoro-phenyl)-5-hydroxy-methyl oxazolidin-2-one dihydrogen phosphate to an acid solution to thereby form crystallized (*R*)-3-(4-(2-(2-methyl-tetrazol-5-yl)pyridin-5-yl)-3-fluoro-phenyl)-5-hydroxy-methyl oxazolidin-2-one dihydrogen phosphate;

filtering the crystallized (*R*)-3-(4-(2-(2-methyl-tetrazol-5-yl)pyridin-5-yl)-3- fluoro-phenyl)-5-hydroxy-methyl oxazolidin-2-one dihydrogen phosphate from a supernatant; and

drying the resulting crystallized (*R*)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate.


12. The process of claim 11

wherein the acid solution comprises (a) HCl and ethanol, or (b)_HCl and tetrahydrofuran.

13. A reaction mixture comprising the crystalline particles of any one of claims 1-7 and a base.


14. The reaction mixture of claim 13, wherein the base is sodium hydroxide.

15. A pharmaceutical composition comprising a lyophilisate of the reaction mixture according to claim 13 or 14, the pharmaceutical composition comprising:




wherein R=PO(ONa)2,

and at least one compound of:



or



, and

at least one pharmaceutically acceptable carrier, excipient or diluent.

16. Use of the pharmaceutical composition of claim 15 in the manufacture of a medicament for treating a bacterial infection in a subject in need thereof.

17. The use of the pharmaceutical composition of claim 16, wherein the bacterial infection results from a Gram-positive bacterium.

18. The use of the pharmaceutical composition of claim 10, wherein the bacterial infection results from a Gram-positive bacterium.

19. The use of the pharmaceutical composition of claim 18, wherein the pharmaceutical composition is for administration in an amount of from about 1 mg to about 500 mg of (*R*)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate.

20. The use of the pharmaceutical composition of claim 19, wherein the pharmaceutical composition is for administration in an amount of from about 5 mg to about 200 mg.

21. The use of the pharmaceutical composition of claim 19, wherein the pharmaceutical composition is for administration in an amount of about 200 mg.